CTOs on the Move

Circle Pharma

www.circlepharma.com

 
Circle Pharma initiated operations in June 2014 with seed funding from Pfizer, Inc. and Mission Bay Capital, LLP; we received additional seed funding from ShangPharma Investment Group Limited in November 2015.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.circlepharma.com
  • 280 Utah Avenue Suite 100
    South San Francisco, CA USA 94080
  • Phone: 650.392.0363

Executives

Name Title Contact Details

Funding

Circle Pharma raised $45M on 03/17/2020

Similar Companies

LGM Pharma

LGM Pharma is an innovation-driven API company, involved in distribution of quality cGMP pharma ingredients to leading pharmaceutical companies. We specialize in streamlining the API supply chain management throughout all development and commercial stages while providing complete technical capabilities and expert regulatory support.

LifeTek Solutions

LifeTek Solutions is a Blue Bell, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Retia Medical

Retia Medical provides accurate, simple, low-cost cardiac output monitoring.

Institutional Pharmacy Solutions

Institutional Pharmacy Solutions is a Montgomery, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

UroGen

UroGen Pharma is a biopharmaceutical company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel™ drug delivery technology platform, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery platform has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment. Our promising pipeline: Ranging from pre-clinical to Phase III, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology. Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; these connections are vital to our commitment to offer new pathways and advance solutions. We currently have an exclusive worldwide license agreement with Allergan™ to evaluate the RTGel platform, an early-stage feasibility agreement with Janssen Pharmaceuticals™, and are continually evaluating new opportunities.